InMed Pharmaceuticals has entered into a service contract with Brio Financial Group to provide senior financial leadership and bookkeeping services. Pursuant to the Contract, Mr. Jonathan Tegge, a member of Brio, will assume the role of Interim Chief Financial Officer for the Company effective December 12, 2022.
Brio is a financial and management consulting group based in Bridgewater, New Jersey. The firm provides outsourced financial management and financial reporting support to small and middle-market entities. Currently, the team provides consulting services to over 50 private and publicly traded companies.
Additionally, the Company announces that its auditor, KPMG LLP, has resigned effective as of December 8, 2022, and that the Audit Committee of the Board of Directors of the Company approved the engagement of Marcum LLP as its auditor, subject to Marcum's completion of their client acceptance procedures. Marcum will stand for an appointment at the Company's Annual General Meeting, currently scheduled for Thursday, December 15, 2022. KPMG has confirmed that there are no reportable events (as such term is defined in National Instrument 51-102 – Continuous Disclosure Obligations ("NI 51-102")).
Eric A. Adams, Chief Executive Officer of InMed, commented, "We are delighted to engage Marcum as the Company's new auditors. We believe that Marcum's breadth of expertise and its focus on mid-sized companies, including cross-border operations, makes Marcum well suited to support our efforts to deliver the high level of financial transparency and reporting to which our shareholders are accustomed."
InMed has provided KPMG with a copy of Form 8-K announcing their resignation, and KPMG have furnished a letter addressed to the Securities and Exchange Commission stating that it has no disagreement with the disclosures therein.
For more information: